A Phase I/II Trial of BMS-754807 in Combination With Trastuzumab (Herceptin®) in Subjects With Advanced or Metastatic Her-2-positive Breast Cancer
For additional information on this trial, please call (910) 558-2913
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The dose escalation portion will determine the MTD and recommended Phase 2 dose or dose range of BMS-754807 when administered orally on a daily schedule in combination with trastuzumab administered at standard doses IV on a weekly basis
Every 30 days until MTD is reached
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Australia: Department of Health and Ageing Therapeutic Goods Administration
CA191-004
NCT00788333
July 2009
November 2011
Name | Location |
---|